Biocon Q4 FY26 Revenue Rises 10% YoY

Biocon reports Q4 FY26 revenue of ₹4,569 Cr, a 10% YoY increase, driven by 12% growth in Biosimilars.
Full-year FY26 revenue grew 14% to ₹17,270 Cr, with Net Profit (before exceptions) surging 323% to ₹436 Cr.
Company completed integration of Biocon Biologics, transitioning from investment phase to execution and value creation.
FY27 focus is on scaling recent biosimilars launches, improving generics profitability, and driving operating leverage.